Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
With all respect, people who are worrying bills are unlikely investors in R&D bio and aim in general. MM are taking advantage on thin SELL stream to push price down. Creating more concerns amongst folks seeing their profits disappearing or loses being magnified. Bottom line, no change in core news. 55% partial reduction and we should be worried about price drop?
Absolutely not. Stay calm, what Netflix lady chattery will definitely calm your nerves.
The next scientific update and progress report from the trial is going to inform the market and big pharma how successful the modi1 platform is. Based on previous updates RNS+AGM+Lady X chats, we expect result to be breaking news. All is pointing in this direction and accumulate is the only sensible option if opportunity presents itself. Update is imminent, we need to be patient as exit may cost more when trying to buy back.
The stars point to England Argentina Final. The revenge of the hand of G-d goal. Well there is a probability for that as well. Slim… but slim can always go through.
Ruck, 100% probability for the price to go up or down. That is over a period of time excluding sideways. That is like saying that tax and death are unavoidable. No need for university degree to come to this conclusion Loll. Anyhow, good luck for today , next week, and the coming new year. May it be full with good health and fortune for all of us.
…can go up or down.
Good the distinguished analysis did not consider sideways. I’m sure there is a probability for that as well.
Come on England!
Don’t think it’s an in-depth analysis. They are puzzled as to why they have not recommended SC in their periodical publication and trying to find a reasonable answer to that. Coming back to probabilities…I am confident that Vulpes didn’t use this as their basis for inverting in SC. Beside, they are so many moving partials to base one’s assessment on that. Well if you can suggest a model, then your are probably a better mathematician than me. No disrespect to any analysis including Motley, the bottom line is less than satisfactory.
He thinks it’s pure speculative, why, because “If good news comes through, in the form of successful trial results, more licensing deals or a takeover bid by a bigger pharma rival, I think Scancell shares could rocket in 2023. But equally, if there is disappointing news from a trial, the Scancell share price could crash.”
Well, what he is saying is that price can go up or down. What a breakthrough conclusion.
Partial response is expected soon to be transformed to major response. Melting is seems to go full steam ahead. Lady X is expecting to have another checkpoint in 12 weeks time. In case there is a linear relationship time/shrinkage, than the inoperable disease may vanish from the radiography screen. If that is not a miracle, what is.
Bion… ?after all the years. Don’t think so. Their platform is tailor made and may want to keep it this way. Beside, maintaining a steady stream of income may not be as urgent as it is for other big Pharma , Merck and the like of them. Hence pending outcome of current trial, which all indicators pointing to outstanding outcome we may witness something extraordinary.
30p is annoyingly modest. If it safe effective and comparably simple to administrate and response deviation in the cohort is less than significant, than that will ignite the debate, imagination and market value.
Is it safe ? We know the dose went up over the trial life cycle.
If it effective ? We know response was over 30% reduction. Albeit exhibit in one patient…is there is another drug in the billion dollar market that is capable to deliver that?
Simple to admin ? I think we can say yes to that.
Next update will give us the clues as to how extraordinary this platform is.